STOCK TITAN

Korsana director plans sale of 100 shares on Nasdaq

Korsana Biosciences director Errol B. De Souza files a Form 144 to sell 100 shares, after selling 2,139 shares for $74,843.61 in the prior three months.

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Korsana Biosciences, Inc. (KRSA) director Errol B. De Souza has filed a Form 144 notice to sell 100 shares of common stock through Morgan Stanley Smith Barney, with an indicated aggregate value of $3,499.00 on Nasdaq. The shares to be sold were acquired upon the vesting of restricted stock during the period from September 1, 2024 through October 1, 2024. Over the prior three months, De Souza reported sales of 2,139 shares of common stock for $74,843.61.

Positive

  • None.

Negative

  • None.
Shares to be sold 100 shares Common stock subject to the current Form 144 notice
Proposed sale value $3,499.00 Aggregate market value of the 100 shares listed for sale
Shares sold in past three months 2,139 shares Common stock sales reported during the three months prior to the notice
Proceeds from past three-month sales $74,843.61 Total consideration for 2,139 shares sold in the prior three months
Restricted stock vesting period September 1, 2024 to October 1, 2024 Period when the securities to be sold were acquired upon vesting
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock financial
"securities to be sold were acquired upon the vesting of restricted stock"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
NASDAQ market
"45541425 | 09/22/2026 | NASDAQ"
The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Korsana Biosciences (KRSA)?

The filing states that director Errol B. De Souza intends to sell 100 shares of Korsana Biosciences common stock under Rule 144, with an indicated aggregate value of $3,499.00, through Morgan Stanley Smith Barney on Nasdaq.

How many KRSA shares has Errol B. De Souza sold recently?

Over the prior three months, Errol B. De Souza reported selling 2,139 shares of Korsana Biosciences common stock, for total proceeds of $74,843.61, as disclosed in the Form 144 under securities sold during the past three months.

What amount of Korsana Biosciences (KRSA) stock is covered by the new Form 144?

The new Form 144 notice covers 100 shares of Korsana Biosciences common stock, with an indicated aggregate value of $3,499.00, proposed to be sold through Morgan Stanley Smith Barney on Nasdaq.

How were the KRSA shares to be sold by Errol B. De Souza obtained?

The notice states that the securities to be sold were acquired upon the vesting of restricted stock during the period from September 1, 2024 through October 1, 2024.

Who is the broker handling the planned KRSA share sale under Form 144?

The Form 144 lists Morgan Stanley Smith Barney LLC Executive Financial Services at 1 New York Plaza, New York, as the broker for the proposed sale of 100 shares of Korsana Biosciences common stock on Nasdaq.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading